부산대학교 도서관

Background Knowledge of the role of the receptor for advanced glycation end products ( RAGE), particularly its soluble form (s RAGE), and of its advanced glycation end product ( AGE) ligand, N-(carboxymethyl)lysine adducts ( CML), is limited in chronic heart failure ( CHF) and in chronic obstructive pulmonary disease ( COPD). We evaluated whether the AGE/ RAGE system is activated in stable CHF and COPD, and whether plasma s RAGE and CML levels are affected by clinical and functional parameters. Materials and methods We measured plasma levels of s RAGE and CML using a sandwich enzyme-linked immunosorbent assay ( ELISA) in 143 subjects, aged ≥ 65 years, divided into five groups: 58 with CHF, 23 with COPD, 27 with CHF+ COPD and 35 controls (17 healthy smokers and 18 healthy nonsmokers). Individuals with diabetes were excluded from the study. Results Plasma levels of s RAGE and CML were higher in CHF patients than in controls [s RAGE: 0·48 (0·37-0·83) vs. 0·42 (0·29-0·52) ng/mL, P = 0·01; CML: 1·95 (1·58-2·38) vs. 1·68 (1·43-2·00) ng/mL, P = 0·01]. By contrast, s RAGE and CML were not different between both COPD and CHF+ COPD patients and controls ( P > 0·05). N-terminal pro-brain natriuretic peptide ( Nt-pro BNP) correlated with s RAGE, but not with CML, in the patient groups: CHF ( r = 0·43, P < 0·001), COPD ( r = 0·77, P < 0·0001) and CHF/ COPD ( r = 0·43, P = 0·003). Conclusions Plasma levels of s RAGE and CML are increased in CHF, but not in COPD patients. The robust association between NT-pro BNP, a diagnostic and prognostic marker in CHF, and sRAGE concentrations might suggest a possible BNP pathway of amplification of inflammation via the AGE/ RAGE system. [ABSTRACT FROM AUTHOR]